Bicycle Therapeutics plc(BCYC)

$4.33—Stale · unknown old

Chart

Bicycle Therapeutics plc(BCYC)

NASDAQ • Last print unknown ago

$4.33—Stale · unknown old

Chart Studio

BCYC(BCYC)

BCYC

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.40

Oct 29, 2026 · Reports before open

Revenue Estimate

$12M

Analyst Sentiment

Wall St. Consensus

Buy

20 analysts·High coverage

Score

17 Buy (85%)3 Hold (15%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1785%

Hold

315%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$8.00

+84.8%

Consensus

$12.00

+177.1%

Bull

$12.00

+177.1%

12-Month Target Range20 analysts

$8.00$12.00$12.00

Current $4.33Consensus

Current Price

$4.33

Upside to Consensus

$7.67

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-51.60%

EPS—

FY2028

Rev+89.29%

EPS—

FY2029

Rev+63.27%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$19M	$9M	$18M	$29M	$138M
Low	$19M	$2M	$9M	$14M	$69M
High	$20M	$17M	$28M	$47M	$224M
EBITDA Avg	$-19M	$-9M	$-18M	$-29M	$-138M
Low	$-20M	$-17M	$-28M	$-47M	$-224M
High	$-19M	$-2M	$-9M	$-14M	$-69M
EBIT Avg	$-19M	$-9M	$-18M	$-29M	$-138M
Low	$-20M	$-17M	$-28M	$-47M	$-224M
High	$-19M	$-2M	$-9M	$-14M	$-69M
Net Income Avg	$-182M	$-173M	$-198M	$-159M	$-95M
Low	$-208M	$-215M	$-281M	$-288M	$-171M
High	$-100M	$-98M	$-86M	$-55M	$-33M
EPS Avg	$-2.43	$-2.32	$-2.55	$-2.30	$-1.37
Low	$-3.01	$-3.10	$-4.06	$-4.15	$-2.47
High	$-1.44	$-1.42	$-1.24	$-0.80	$-0.48
Analysts (Rev / EPS)	7 / 7	7 / 7	9 / 7	4 / 2	4 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$12M	$2M	$1M	$1M	$1M	$1M
Low	$5M	$24,767	$234,057	$216,069	$216,551	$216,965
High	$19M	$3M	$2M	$2M	$2M	$2M
EBITDA Avg	$-12M	$-2M	$-1M	$-1M	$-1M	$-1M
Low	$-19M	$-3M	$-2M	$-2M	$-2M	$-2M
High	$-5M	$-24,767	$-234,057	$-216,069	$-216,551	$-216,965
EBIT Avg	$-12M	$-2M	$-1M	$-1M	$-1M	$-1M
Low	$-19M	$-3M	$-2M	$-2M	$-2M	$-2M
High	$-5M	$-24,767	$-234,057	$-216,069	$-216,551	$-216,965
Net Income Avg	$-28M	$-31M	$-40M	$-41M	$-43M	$-45M
Low	$-61M	$-66M	$-94M	$-98M	$-102M	$-107M
High	$-4M	$28M	$1M	$1M	$1M	$1M
EPS Avg	$-0.40	$-0.44	$-0.57	$-0.59	$-0.61	$-0.64
Low	$-0.88	$-0.94	$-1.35	$-1.40	$-1.46	$-1.53
High	$-0.05	$0.40	$0.02	$0.02	$0.02	$0.02
Analysts (Rev / EPS)	5 / 5	5 / 5	4 / 3	4 / 3	4 / 3	4 / 3

Earnings Surprises

Recent Analyst Actions

Apr 30, 2026Jefferies

Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies

Target:$12.00

+154.2%from $4.72

Apr 8, 2026Morgan Stanley

Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley

Target:$12.00

+141.0%from $4.98

Mar 17, 2026Truist Financial

Bicycle Therapeutics (BCYC) PT Lowered to $8 at Truist Securities

Target:$8.00

+57.2%from $5.09

Mar 17, 2026Morgan Stanley

Morgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right call'

Target:$13.00

+153.4%from $5.13

Nov 24, 2025Truist Financial

Bicycle Therapeutics initiated with a Hold at Truist

Target:$10.00

+58.2%from $6.32

Oct 31, 2025JMP Securities

Bicycle Therapeutics price target raised to $12 from $10 at Citizens JMP

Target:$12.00

+37.0%from $8.76

Oct 31, 2025RBC Capital

RBC downgrades Bicycle Therapeutics on slow pipeline progress

Target:$11.00

+25.6%from $8.76

Aug 11, 2025RBC Capital

Bicycle Therapeutics price target raised to $27 from $25 at RBC Capital

Target:$27.00

+255.8%from $7.59

May 5, 2025Morgan Stanley

Bicycle Therapeutics price target raised to $17 from $15 at Morgan Stanley

Target:$17.00

+87.6%from $9.06

Dec 18, 2024JMP Securities

Bicycle Therapeutics price target lowered to $26 from $32 at JMP Securities

Target:$26.00

+69.7%from $15.32

Oct 24, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Bicycle Therapeutics (BCYC)

Target:$48.00

+89.6%from $25.32

Oct 24, 2024B.Riley Financial

B.Riley Reiterates Neutral Rating on Bicycle Therapeutics (BCYC)

Target:$28.00

+10.6%from $25.32

Sep 16, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Bicycle Therapeutics (BCYC)

Target:$55.00

+103.6%from $27.02

Oct 7, 2021Roth Capital

Bicycle Therapeutics (BCYC) PT Raised to $65 at Roth Capital

Target:$65.00

+33.5%from $48.69

Oct 7, 2021Piper Sandler

Bicycle Therapeutics price target raised to $76 from $46 at Piper Sandler

Target:$76.00

+56.1%from $48.69

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance